Want to see NMTC full AI Analyst Report?
Earnings Data
Report Date
Aug 19, 2026Before Open (Confirmed)
Period Ending
2026 (Q3)Consensus EPS Forecast
-0.58Last Year’s EPS
-0.18Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call conveyed meaningful operational and clinical progress — notably 72% Q2 product revenue growth, publication and clinical wins, ISO audit progress, regained NASDAQ compliance, and no debt — alongside strategic hires and partnership momentum. However, material financial and timing challenges temper the optimism: cash balances declined sharply (~57.6%), there was no license revenue this year (vs. $3.0M prior), six-month net loss widened to $3.5M, and gross margins compressed. Several growth catalysts (international rollout, drug delivery commercial availability, spinal cord stimulation timeline) remain contingent on future milestones or partner actions and thus introduce execution and timing risk. Balancing the clear operational wins against the pronounced near-term liquidity and revenue-recognition headwinds yields a neutral overall view.Company Guidance
Strong Q2 Product Revenue Growth
Product revenue for OneRF brain ablation system grew 72% year-over-year to $2.4M in Q2 FY2026 (from $1.4M in Q2 FY2025); product revenue for the six months ended March 31, 2026 was $5.3M, up 13% year-over-year (from $4.7M).
Clinical and Publication Milestones
Peer-reviewed case series published validating real-time temperature monitoring in SEEG-guided RF ablation; OneRF highlighted at AANS; OneRF trigeminal nerve ablation system completed 16 cases under limited market release with all patients reportedly pain-free.
Regulatory / Quality Progress for International Expansion
Completed Stage 2 ISO 13485 audit for the Minnesota facility and remain bullish on certification in the latter part of 2026 — a key step toward enabling international distribution.
Strategic Partnerships and Commercial Progress
Ongoing partnership with Zimmer Biomet for domestic and international commercialization; collaboration announced with University of Minnesota Neurology Division to advance drug delivery studies; drug delivery system on track for availability in H2 FY2026 for investigational/animal studies.
Corporate and Governance Improvements
Regained NASDAQ compliance following a 1-for-6 reverse split; appointed David Wambeke as Chief Business Officer (purchased 1M pre-split shares); new high-net-worth investor acquired ~7.4% of outstanding common stock.
Positive Product Gross Profit and Expense Discipline
Product gross profit was $1.3M (53.8% of product revenue) in Q2 FY2026; total operating expenses were largely flat year-over-year at $3.4M in Q2, with SG&A flat at $1.9M and R&D stable at $1.5M.
No Debt and Receivables Near-Term Conversion
NeuroOne reported no debt as of March 31, 2026 and had $2.4M in accounts receivable expected to convert to cash in Q3 based on normal collection patterns.
NMTC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NMTC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2026 | $4.33 | $4.39 | +1.39% |
Feb 17, 2026 | $4.88 | $4.07 | -16.50% |
Dec 17, 2025 | $4.24 | $4.01 | -5.47% |
Aug 14, 2025 | $5.16 | $4.98 | -3.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does NeuroOne Medical Technologies (NMTC) report earnings?
NeuroOne Medical Technologies (NMTC) is schdueled to report earning on Aug 19, 2026, Before Open (Confirmed).
What is NeuroOne Medical Technologies (NMTC) earnings time?
NeuroOne Medical Technologies (NMTC) earnings time is at Aug 19, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NMTC EPS forecast?
NMTC EPS forecast for the fiscal quarter 2026 (Q3) is -0.58.